Increased risk of suicidal thoughts, self-harm & suicide-related events. Increased incidence of extrapyramidal symptoms. Tardive dyskinesia. Somnolence & related symptoms eg, sedation, orthostatic hypotension & related dizziness. Sleep apnea syndrome. Patients receiving concomitant CNS depressants & who have history or are at risk eg, overwt/obese, male patients. Anti-cholinergic (muscarinic) effects. Patients w/ current diagnosis or prior history of urinary retention, significant prostatic hypertrophy, intestinal obstruction or related conditions, increased IOP or narrow angle glaucoma; history of seizures. CV & cerebrovascular disease or other conditions predisposing to hypotension or family history of QT prolongation. Patients w/ suspected cardiomyopathy or myocarditis. Neuroleptic malignant syndrome. Severe neutropenia w/o infection. Agranulocytosis in patients w/o pre-existing risk factors. Discontinue in patients w/ neutrophil count <1.0 x 109
/L. Monitor wt; blood glucose. Increased triglycerides, LDL & total cholesterol & decreased HDL cholesterol. Medicines known to increase QT interval or w/ neuroleptics, especially in elderly, in patients w/ congenital long QT syndrome, CHF, heart hypertrophy, hypokalaemia or hypomagnesaemia. Patients w/ history of alcohol or drug abuse. Patients at risk for aspiration pneumonia. Venous thromboembolism, constipation & intestinal obstruction, pancreatitis. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients should be advised not to drive or operate machinery. Pregnancy. Avoid breast-feeding during treatment. Neonatal w/drawal symptoms.